Trial Profile
Randomised study assessing efficacy and safety of telaprevir evey 8 or 12 hours with peginterferon alfa 2b and ribavirin in HCV patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2013
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary) ; Telaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 22 Nov 2013 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 22 May 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 25 Feb 2013 Planned number of patients changed from 80 to 50 as reported by University Hospital Medical Information Network - Japan.